Vertex Announces Day 90 Data For First Patient In Phase 1/2 Clinical Trial Dosed With VX-880; Demonstrated Restoration Of Insulin Production, Showed 91% Decrease In Daily Insulin Requirement And 'robust improvements in glucose control'